Compare Inovio Pharmaceuticals Inc (INO) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs NextEra Energy, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while NextEra Energy, Inc. trades at $88 (market cap $183.53B). The key difference: NextEra Energy, Inc. is far larger — about 2055.9× Inovio Pharmaceuticals Inc's market cap, and NextEra Energy, Inc. pays a 2.83% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NEE | |
|---|---|---|
Market Cap | $89.27M | $183.53B |
Sector | Health | Utilities |
52-Week High | $2.87 | $97.88 |
52-Week Low | $1.05 | $69.77 |
Enterprise Value | $60.28M | $285.94B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
NextEra Energy (NEE) trades at $87.93, down 0.98% with a bearish technical signal. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though Q4 2025 earnings missed expectations. Recent news highlights the proposed Dominion Energy combination and $59 billion capital expenditure plan through 2032. Analyst consensus remains strongly bullish with 66.7% buy ratings and $101.88 price target, representing 16% upside potential.
NEE offers solid long-term growth prospects from renewable energy expansion and regulatory advantages, but faces execution risks from massive capital spending and integration challenges from the Dominion merger. Current valuation at 22.34 P/E appears reasonable given growth trajectory, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
